Company Overview
Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.
This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.
The Tango labs and offices are located at 201 Brookline Avenue, in the Fenway area of Boston, Massachusetts.
Summary
We are seeking a Global Program Operations Head (GPOH), reporting into the Vice President, Clinical Operations, to lead the strategic and operational execution of a portfolio of clinical trials within a designated disease area. This role partners cross-functionally with Clinical, Medical, Regulatory, and Operational Excellence to ensure programs are aligned with corporate goals, regulatory requirements, and operational feasibility.
You will drive program-level strategy, oversee trial execution, and manage Contract Research Organizations (CROs) and external vendors, ensuring delivery against timelines, budgets, and quality expectations. Additionally, you will lead and develop a high-performing clinical operations team while supporting governance, risk management, and inspection readiness in a fast-paced biotech environment.
Your Role
- Oversee the strategic and operational execution of a portfolio of clinical trials within a designated disease area
- Ensure alignment with corporate goals and regulatory standards
- Represent Global Clinical Operations in Global Program Teams (GPTs) and sub-teams, contributing to program-level strategy and operational planning
- Collaborate with Medical and Regulatory Directors to ensure clinical strategies are scientifically sound, meet regulatory requirements, and are operationally feasible
- Partner with Operational Excellence & Clinical Compliance to align on risk assessment, trial- and site management metrics, KPIs, and KRIs
- Define and implement outsourcing strategies in partnership with the VP of Global Clinical Operations and Head of Clinical Sourcing & Contracting
- Lead the selection, negotiation, contracting, and performance oversight of CROs and external vendors
- Monitor trial progress and key deliverables, guiding Clinical Trial Teams (CTTs) in execution planning, issue resolution, and risk mitigation
- Manage program and trial budgets, ensuring accurate forecasting, cost control, and financial accountability
- Track CRO/ vendor performance using metrics, KPIs, KRIs and participate in governance meetings to address escalated issues and drive continuous improvement
- Provide regular updates on trial progress to internal governance bodies, including GPT and Executive Leadership Team
- Support inspection readiness activities and represent the organization during Health Authority inspections
- Provide leadership, coaching, and performance management to Clinical Trial Leaders (CTLs), Clinical Contract Managers (CTMs), Clinical Trial Specialists (CTSs), and Site Management Leader (SMLs)
- Set clear objectives, deliver ongoing feedback, and develop tailored development plans to support team growth and capability building
- Oversee hiring, onboarding, and training of new team members, fostering a culture of operational excellence and continuous learning
What You Bring
- 12+ years of trial management experience with 7+ years in leadership position
- Bachelor’s degree in Life Sciences, Pharmacy or related field (required). Advanced degree, e.g., MS, PharmD, PhD, MBA (preferred).
- Significant experience working in global clinical development organization
- Experience in Oncology development (preferred)
- Direct experience with health authority inspections (FDA, EMA, MHRA, etc.) incl. sponsor GCP inspections
- Significant experience in outsourcing and oversight
- Expert knowledge in ICH-GCP, FDA guidelines, EU CTR and other relevant guidelines
- Expert knowledge in financial planning, tracking, and reporting
- Expert knowledge in risk assessment and management on program and trial-level
- Executive presence and strategic thinking on corporate-, program-, and trial-level
- Strong decision‑making and sound judgment
- Strong leadership and interpersonal skills
- High credibility with senior leadership
- Familiarity with clinical trial systems (e.g., CTMS, eTMF, EDC, IRT, eCOA) and operational metrics, KPIs, and KRIs
- Willingness to travel, as required (typically 10–20%)
#LI-Hybrid
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status
Skills Required
- 12+ years of trial management experience
- 7+ years in leadership position
- Bachelor's degree in Life Sciences, Pharmacy or related field
- Significant experience in global clinical development organization
- Experience in Oncology development
- Direct experience with health authority inspections (FDA, EMA, MHRA, etc.)
- Significant experience in outsourcing and oversight
- Expert knowledge in ICH-GCP, FDA guidelines, EU CTR
- Expert knowledge in financial planning, tracking, and reporting
- Expert knowledge in risk assessment and management
- Strong leadership and interpersonal skills
- Familiarity with clinical trial systems
What We Do
Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.
.png)
